Growth Stalk Holdings Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Growth Stalk Holdings's earnings have been declining at an average annual rate of -28.6%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 144.2% per year.
Belangrijke informatie
-28.6%
Groei van de winst
23.8%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 6.0% |
| Inkomstengroei | 144.2% |
| Rendement op eigen vermogen | -81.1% |
| Nettomarge | -53.3% |
| Laatste winstupdate | 31 Dec 2023 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Geen updates
Opbrengsten en kosten
Hoe Growth Stalk Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 23 | 1 | 0 | 1 | 0 |
| 31 Mar 23 | 0 | 0 | 1 | 0 |
| 31 Dec 22 | 0 | 0 | 1 | 0 |
| 30 Sep 22 | 0 | 0 | 0 | 0 |
| 30 Jun 22 | 0 | 0 | 0 | 0 |
| 31 Mar 22 | 0 | 0 | 0 | 0 |
| 31 Dec 21 | 0 | 0 | 0 | 0 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
Kwaliteitswinsten: GSTK is currently unprofitable.
Groeiende winstmarge: GSTK is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Insufficient data to determine if GSTK's year-on-year earnings growth rate was positive over the past 5 years.
Versnelling van de groei: Unable to compare GSTK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: GSTK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement op eigen vermogen
Hoge ROE: GSTK has a negative Return on Equity (-81.1%), as it is currently unprofitable.